TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLTX Stock 12 Month Forecast
Average Price Target
$15.38
▲(14.86% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $15.38 with a high forecast of $30.00 and a low forecast of $5.00. The average price target represents a 14.86% change from the last price of $13.39.
FDA moving to one trial for approval could be positve for MoonLake, says CantorFDA moving to one trial for approval could be positve for MoonLake, says Cantor
MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman SachsMoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs
Guggenheim cuts MoonLake Immunotherapeutics price target, removes as Best IdeaGuggenheim cuts MoonLake Immunotherapeutics price target, removes as Best Idea
MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe ResearchMoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research
FDA moving to one trial for approval could be positve for MoonLake, says CantorFDA moving to one trial for approval could be positve for MoonLake, says Cantor
MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman SachsMoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs
Guggenheim cuts MoonLake Immunotherapeutics price target, removes as Best IdeaGuggenheim cuts MoonLake Immunotherapeutics price target, removes as Best Idea
MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe ResearchMoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +13.14% per trade.
trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +29.65% per trade.
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +10.45% per trade.
trades and holding each position for 2 Years would result in 35.29% of your transactions generating a profit, with an average return of -20.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLTX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
8
8
10
14
9
Buy
13
14
10
3
3
Hold
1
5
5
7
3
Sell
0
1
2
2
1
Strong Sell
0
0
0
0
0
total
22
28
27
26
16
In the current month, MLTX has received 12Buy Ratings, 3Hold Ratings, and 1Sell Ratings. MLTX average Analyst price target in the past 3 months is 15.38.
Each month's total comprises the sum of three months' worth of ratings.
MLTX Financial Forecast
MLTX Earnings Forecast
Next quarter’s earnings estimate for MLTX is -$0.99 with a range of -$1.14 to -$0.73. The previous quarter’s EPS was -$1.10. MLTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for MLTX is -$0.99 with a range of -$1.14 to -$0.73. The previous quarter’s EPS was -$1.10. MLTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.
No data currently available
MLTX Sales Forecast
Next quarter’s sales forecast for MLTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MLTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.
Next quarter’s sales forecast for MLTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MLTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.
MLTX Stock Forecast FAQ
What is MLTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Moonlake Immunotherapeutics’s 12-month average price target is 15.38.
What is MLTX’s upside potential, based on the analysts’ average price target?
Moonlake Immunotherapeutics has 14.86% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLTX a Buy, Sell or Hold?
Moonlake Immunotherapeutics has a consensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 2 sell ratings.
What is Moonlake Immunotherapeutics’s price target?
The average price target for Moonlake Immunotherapeutics is 15.38. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $30.00 ,the lowest forecast is $5.00. The average price target represents 14.86% Increase from the current price of $13.39.
What do analysts say about Moonlake Immunotherapeutics?
Moonlake Immunotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of MLTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.